2 weeks Ago By Defense World Staff
Townsquare Capital LLC grew its stake in shares of Edwards Lifesciences Co. ( NYSE:EW – Free Report ) by 24.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission.
The firm owned 6,501 shares of the medical research company’s stock after buying an additional 1,293 shares during the period. Townsquare Capital LLC’s holdings in Edwards Lifesciences were worth $481,000 as of its most recent SEC filing. A number of other institutional investors and hedge funds have also made changes to their positions in the company.
Crux Wealth Advisors purchased a new stake in Edwards Lifesciences during the fourth quarter worth approximately $478,000. Heritage Trust Co acquired a new stake in Edwards Lifesciences in the 4th quarter valued at $205,000. Covestor Ltd raised its position in Edwards Lifesciences by 13.
4% in the fourth quarter. Covestor Ltd now owns 1,647 shares of the medical research company’s stock valued at $122,000 after purchasing an additional 195 shares during the period. Argent Trust Co purchased a new position in Edwards Lifesciences in the fourth quarter valued at about $208,000.
Finally, Kennedy Capital Management LLC boosted its position in shares of Edwards Lifesciences by 25.8% in the fourth quarter. Kennedy Capital Management LLC now owns 192,518 shares of the medical research company’s stock worth $14,252,000 after buying an additional 39,472 shares during the period.
79.46% of the stock is currently owned by institutional investors and hedge funds. Analysts Set New Price Targets Several equities analysts recently commented on EW shares.
Piper Sandler boosted their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th.
Royal Bank of Canada reissued an “outperform” rating and set a $85.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Morgan Stanley lifted their price target on shares of Edwards Lifesciences from $70.
00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Canaccord Genuity Group upped their price objective on shares of Edwards Lifesciences from $68.
00 to $71.00 and gave the company a “hold” rating in a research report on Thursday, February 13th. Finally, Truist Financial dropped their target price on Edwards Lifesciences from $78.
00 to $75.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and ten have assigned a buy rating to the company’s stock.
According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $78.55. Edwards Lifesciences Stock Up 0.
5 % Shares of Edwards Lifesciences stock opened at $71.56 on Monday. The stock has a market capitalization of $42.
07 billion, a price-to-earnings ratio of 10.27, a PEG ratio of 4.82 and a beta of 1.
15. The business’s 50 day simple moving average is $71.31 and its 200-day simple moving average is $70.
92. The company has a current ratio of 3.46, a quick ratio of 2.
89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co.
has a twelve month low of $58.93 and a twelve month high of $95.25.
Edwards Lifesciences ( NYSE:EW – Get Free Report ) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.
55 by $0.04. Edwards Lifesciences had a net margin of 72.
93% and a return on equity of 19.40%. Equities research analysts forecast that Edwards Lifesciences Co.
will post 2.45 earnings per share for the current year. Insider Activity In other Edwards Lifesciences news, CFO Scott B.
Ullem sold 11,250 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.
00. Following the sale, the chief financial officer now directly owns 30,561 shares in the company, valued at approximately $2,315,301.36.
The trade was a 26.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link .
Also, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.
42, for a total transaction of $438,574.38. Following the completion of the transaction, the director now owns 60,372 shares of the company’s stock, valued at $4,613,628.
24. This trade represents a 8.68 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . Over the last 90 days, insiders have sold 71,853 shares of company stock valued at $5,163,062. Insiders own 1.
29% of the company’s stock. Edwards Lifesciences Profile ( Free Report ) Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Read More Five stocks we like better than Edwards Lifesciences What Does Downgrade Mean in Investing? With a 60%+ Upside, There’s Plenty to Love About Lovesac What is the Dow Jones Industrial Average (DJIA)? J.B. Hunt Transport Overcorrects Into a Buying Opportunity Diversification Can Smooth Returns And Mitigate Portfolio Risk AppLovin: Can Record Profits Overcome Market Skepticism? Want to see what other hedge funds are holding EW? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. ( NYSE:EW – Free Report ). Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.
com's FREE daily email newsletter ..
